• Consensus Rating: Hold
  • Consensus Price Target: $84.92
  • Forecasted Upside: 27.81 %
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.26 (0.39%)

This chart shows the closing price for INCY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Incyte Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INCY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INCY

Analyst Price Target is $84.92
▲ +27.81% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $84.92, with a high forecast of $108.00 and a low forecast of $63.00. The average price target represents a 27.81% upside from the last price of $66.44.

This chart shows the closing price for INCY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 11 investment analysts is to hold stock in Incyte. This rating has held steady since May 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 7 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/22/2022Evercore ISIDowngradeIn-LineLow
8/3/2022Morgan StanleyLower TargetEqual Weight$77.00 ➝ $76.00N/A
8/3/2022Evercore ISIDowngradeOutperform ➝ Inline$90.00 ➝ $78.00Low
8/3/2022OppenheimerLower Target$109.00 ➝ $98.00Low
8/3/2022GuggenheimDowngradeBuy ➝ NeutralLow
7/28/2022Wells Fargo & CompanyInitiated CoverageEqual Weight$76.00Low
7/20/2022SVB LeerinkBoost TargetUnderperform$58.00 ➝ $63.00Low
5/3/2022Stifel NicolausBoost Target$75.00 ➝ $77.00Low
4/20/2022Morgan StanleyBoost TargetEqual Weight$73.00 ➝ $76.00Low
2/9/2022SVB LeerinkDowngradeMarket Perform ➝ Underperform$60.00 ➝ $56.00Low
2/2/2022Morgan StanleyLower TargetEqual Weight$77.00 ➝ $76.00Low
1/18/2022Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$78.00 ➝ $90.00Medium
1/3/2022GuggenheimLower Target$118.00 ➝ $104.00High
12/17/2021JMP SecuritiesReiterated RatingBuy$108.00High
11/18/2021BMO Capital MarketsInitiated CoverageMarket Perform$75.00Low
11/4/2021JMP SecuritiesLower TargetMarket Outperform$124.00 ➝ $108.00High
11/3/2021OppenheimerLower TargetOutperform$110.00 ➝ $109.00High
10/15/2021Cantor FitzgeraldLower TargetNeutral$104.00 ➝ $79.00Low
10/4/2021Truist FinancialLower TargetBuy$120.00 ➝ $95.00Medium
9/24/2021JMP SecuritiesReiterated RatingBuy$124.00Low
9/23/2021Morgan StanleyLower TargetEqual Weight$85.00 ➝ $80.00Low
9/23/2021Royal Bank of CanadaLower TargetSector Perform$91.00 ➝ $86.00Low
8/4/2021SVB LeerinkLower TargetUnderperform$70.00 ➝ $67.00Low
7/20/2021BenchmarkUpgradeHold ➝ Buy$89.00Medium
6/25/2021Royal Bank of CanadaLower TargetSector Perform$92.00 ➝ $88.00Low
6/15/2021William BlairReiterated RatingOutperformLow
6/15/2021SVB LeerinkReiterated RatingSellLow
5/5/2021Morgan StanleyLower TargetEqual Weight$86.00 ➝ $85.00Low
4/5/2021Morgan StanleyLower TargetEqual Weight$93.00 ➝ $86.00Low
2/10/2021Morgan StanleyLower TargetEqual Weight$97.00 ➝ $93.00Low
2/10/2021SVB LeerinkDowngradeMarket Perform ➝ Underperform$89.00 ➝ $70.00Low
1/7/2021Truist FinancialInitiated CoverageBuy$120.00N/A
1/4/2021GuggenheimUpgradeNeutral ➝ BuyN/A
11/9/2020Morgan StanleyLower TargetEqual Weight$103.00 ➝ $97.00High
11/6/2020BMO Capital MarketsLower TargetMarket Perform$94.00 ➝ $87.00Medium
11/6/2020Royal Bank of CanadaLower TargetSector Perform$96.00 ➝ $86.00Medium
10/15/2020Bank of AmericaLower TargetBuy$113.00 ➝ $110.00Low
10/13/2020Morgan StanleyBoost TargetEqual Weight$100.00 ➝ $103.00Low
8/9/2020CowenReiterated RatingBuyMedium
8/6/2020BMO Capital MarketsBoost TargetMarket Perform$90.00 ➝ $94.00Low
8/6/2020Credit Suisse GroupLower TargetNeutral$100.00 ➝ $97.00Low
8/6/2020Morgan StanleyBoost TargetEqual Weight$95.00 ➝ $100.00Low
8/4/2020MizuhoInitiated CoverageHold$79.00 ➝ $95.00Medium
8/4/2020SVB LeerinkBoost TargetMarket Perform$86.00 ➝ $87.00Low
8/3/2020Royal Bank of CanadaBoost TargetSector Perform$91.00 ➝ $92.00High
7/28/2020JPMorgan Chase & Co.Reiterated RatingHold$99.00Low
7/24/2020William BlairReiterated RatingBuyLow
7/20/2020Credit Suisse GroupBoost TargetNeutral$88.00 ➝ $100.00High
7/17/2020OppenheimerReiterated RatingBuy$121.00High
6/17/2020William BlairReiterated RatingBuyLow
6/16/2020BenchmarkInitiated CoverageHoldLow
6/15/2020OppenheimerInitiated CoverageBuy$120.00Medium
6/4/2020ArgusBoost TargetBuy$92.00 ➝ $124.00High
5/26/2020The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyHigh
5/19/2020Cantor FitzgeraldBoost TargetNeutral$83.00 ➝ $100.00Medium
5/12/2020Morgan StanleyBoost TargetEqual Weight$94.00 ➝ $95.00High
5/6/2020Credit Suisse GroupReiterated RatingHold$88.00Low
5/6/2020BMO Capital MarketsBoost TargetMarket Perform$74.00 ➝ $90.00Low
5/6/2020NomuraReiterated RatingBuy$116.00Low
5/6/2020OppenheimerBoost TargetOutperform$112.00 ➝ $120.00Medium
5/6/2020Royal Bank of CanadaBoost TargetIn-Line ➝ Sector Perform$81.00 ➝ $91.00Medium
5/5/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$89.00 ➝ $99.00Medium
4/29/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$94.00Medium
4/21/2020OppenheimerBoost TargetOutperform$90.00 ➝ $112.00Medium
4/20/2020Piper SandlerBoost TargetOverweight$95.00 ➝ $110.00Low
4/19/2020MizuhoReiterated RatingHold$79.00Low
4/9/2020William BlairReiterated RatingBuyLow
4/8/2020Royal Bank of CanadaReiterated RatingHold$81.00Medium
4/8/2020Nomura SecuritiesReiterated RatingBuy$116.00Medium
4/7/2020OppenheimerBoost TargetOutperform$85.00 ➝ $90.00Low
4/6/2020Piper SandlerReiterated RatingBuyHigh
4/1/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$83.00 ➝ $90.00Medium
3/25/2020OppenheimerLower Target$99.00 ➝ $85.00High
3/24/2020William BlairInitiated CoverageOutperformHigh
3/18/2020Royal Bank of CanadaReiterated RatingHold$81.00Medium
3/13/2020Bank of AmericaUpgradeNeutral ➝ Buy$83.00High
3/11/2020Credit Suisse GroupLower TargetNeutral$86.00 ➝ $81.00Medium
2/19/2020Piper SandlerReiterated RatingBuyLow
2/19/2020Nomura SecuritiesBoost TargetBuy$111.00 ➝ $116.00Low
2/19/2020CowenReiterated RatingBuyLow
2/16/2020JPMorgan Chase & Co.Reiterated RatingBuy$89.00Low
2/16/2020Evercore ISIReiterated RatingBuy$92.00Low
2/13/2020MizuhoReiterated RatingHold$79.00High
2/4/2020Bank of AmericaReiterated RatingNeutral$82.00Low
1/30/2020Royal Bank of CanadaReiterated RatingHold$80.00Medium
1/27/2020Evercore ISIReiterated RatingBuy$92.00Low
1/23/2020Cantor FitzgeraldBoost TargetNeutral$65.00 ➝ $83.00Low
1/14/2020JPMorgan Chase & Co.Reiterated RatingBuyHigh
1/14/2020JMP SecuritiesReiterated RatingOutperform$121.00High
1/13/2020CowenReiterated RatingBuyHigh
1/6/2020Royal Bank of CanadaReiterated RatingHold ➝ NeutralHigh
1/6/2020Morgan StanleyLower TargetEqual Weight$89.00 ➝ $83.00Low
1/3/2020Royal Bank of CanadaLower Target$80.00Medium
1/3/2020The Goldman Sachs GroupLower TargetBuy$122.00 ➝ $107.00High
1/3/2020Credit Suisse GroupLower TargetNeutral$90.00 ➝ $86.00High
1/3/2020OppenheimerLower TargetOutperform$100.00 ➝ $96.00High
1/3/2020BMO Capital MarketsLower TargetMarket Perform$85.00 ➝ $74.00High
1/3/2020CitigroupReiterated RatingOutperform$100.00 ➝ $96.00High
1/3/2020JMP SecuritiesLower TargetMarket Outperform$110.00 ➝ $99.00High
1/3/2020Cantor FitzgeraldLower TargetNeutral$75.00 ➝ $65.00High
1/2/2020MizuhoDowngradeBuy ➝ Neutral$98.00 ➝ $79.00High
1/2/2020Piper Jaffray CompaniesReiterated RatingBuy$95.00High
1/2/2020CowenReiterated RatingBuyHigh
1/2/2020GuggenheimDowngradeBuy ➝ NeutralMedium
12/18/2019MizuhoReiterated RatingBuy$98.00Low
11/27/2019MizuhoReiterated RatingBuy$98.00Low
10/29/2019MizuhoReiterated RatingBuy$95.00Medium
10/2/2019MizuhoInitiated CoverageBuy$95.00Medium
9/30/2019JMP SecuritiesBoost TargetBuy ➝ Market Outperform$107.00 ➝ $110.00Medium
9/27/2019CowenReiterated RatingBuyLow
9/27/2019GuggenheimSet TargetBuy$101.00Low
9/12/2019BMO Capital MarketsInitiated CoverageMarket Perform$85.00High
9/5/2019Morgan StanleyBoost TargetEqual ➝ Equal Weight$82.00 ➝ $87.00High
9/5/2019OppenheimerUpgradeMarket Perform ➝ Outperform$85.00 ➝ $100.00Medium
9/5/2019JMP SecuritiesUpgradeMarket Perform ➝ Outperform$107.00Medium
8/4/2019CowenReiterated RatingBuyLow
7/31/2019SVB LeerinkSet TargetHold$90.00Medium
7/31/2019Nomura SecuritiesBoost TargetBuy$100.00 ➝ $111.00Low
7/31/2019JPMorgan Chase & Co.Reiterated RatingBuy$91.00Low
7/31/2019Morgan StanleyBoost TargetEqual Weight$81.00 ➝ $82.00Low
6/17/2019Piper Jaffray CompaniesReiterated RatingBuyLow
5/27/2019CowenReiterated RatingBuyLow
5/20/2019Credit Suisse GroupInitiated CoverageNeutral$75.00Medium
5/15/2019Piper Jaffray CompaniesBoost TargetOverweight$85.00 ➝ $95.00Low
5/15/2019JPMorgan Chase & Co.Reiterated RatingBuy$90.00Low
5/3/2019BarclaysDowngradeOverweight ➝ Equal Weight$90.00 ➝ $82.00High
4/30/2019JPMorgan Chase & Co.Reiterated RatingBuyHigh
4/22/2019CowenReiterated RatingBuyLow
4/14/2019BarclaysReiterated RatingBuy$90.00High
4/10/2019Stifel NicolausInitiated CoverageHold$82.00 ➝ $82.00Medium
4/7/2019OppenheimerSet TargetHold$85.00Low
4/3/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$89.00High
2/25/2019ArgusBoost TargetBuy ➝ Buy$83.00 ➝ $98.00Low
2/15/2019Raymond JamesSet TargetBuy$100.00Low
2/15/2019Royal Bank of CanadaBoost TargetOutperform$89.00High
2/11/2019JMP SecuritiesReiterated RatingHoldLow
2/5/2019SunTrust BanksBoost TargetBuy$90.00Low
1/24/2019William BlairUpgradeMarket Perform ➝ Outperform$85.00 ➝ $100.00Low
1/23/2019GabelliUpgradeHold ➝ Buy$105.00Medium
1/16/2019UBS GroupDowngradeBuy ➝ Neutral$75.00 ➝ $82.00Medium
1/15/2019The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyHigh
1/10/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
1/3/2019GuggenheimUpgradeNeutral ➝ BuyHigh
12/9/2018CowenReiterated RatingBuyLow
12/3/2018CowenReiterated RatingBuyHigh
10/30/2018JPMorgan Chase & Co.Set TargetBuy$88.00High
10/30/2018CowenReiterated RatingBuyHigh
10/25/2018Raymond JamesReiterated RatingBuy$85.00Low
10/21/2018Cantor FitzgeraldReiterated RatingNeutral ➝ Hold$73.00 ➝ $74.00Low
10/1/2018Cantor FitzgeraldInitiated CoverageNeutral ➝ Neutral$73.00Low
9/24/2018SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$78.00Low
9/17/2018GuggenheimInitiated CoverageNeutralLow
9/15/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
9/13/2018OppenheimerSet TargetHold$70.00Low
9/4/2018CowenReiterated RatingBuyHigh
8/30/2018ArgusSet TargetBuy$83.00Low
8/15/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$74.00Low
8/1/2018JMP SecuritiesDowngradeOutperform ➝ Market PerformLow
8/1/2018JPMorgan Chase & Co.Reiterated RatingBuy$88.00Medium
7/31/2018OppenheimerSet TargetHold$70.00Medium
7/31/2018CowenReiterated RatingBuyHigh
7/27/2018Raymond JamesReiterated RatingBuyMedium
7/17/2018OppenheimerSet TargetMarket Perform ➝ Hold$65.00 ➝ $70.00Low
7/13/2018Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
6/26/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$76.00 ➝ $74.00High
6/24/2018JPMorgan Chase & Co.Reiterated RatingBuy$88.00Medium
6/11/2018Evercore ISIUpgradeIn-Line ➝ Outperform$60.23 ➝ $140.11Medium
6/1/2018OppenheimerSet TargetHold$65.00Low
5/30/2018Piper Jaffray CompaniesInitiated CoverageBuy$85.00Low
5/2/2018CowenReiterated RatingBuyLow
5/1/2018OppenheimerSet TargetHold$65.00Low
5/1/2018Raymond JamesReiterated RatingBuyLow
4/24/2018Raymond JamesReiterated RatingBuyHigh
4/24/2018JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$96.00 ➝ $88.00High
4/23/2018OppenheimerSet TargetHold$65.00High
4/17/2018Credit Suisse GroupSet TargetBuy$78.00Low
4/12/2018UBS GroupUpgradeNeutral ➝ Buy$76.00Low
4/9/2018JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$149.00 ➝ $96.00Low
4/9/2018Credit Suisse GroupLower TargetOutperform$146.00 ➝ $76.00High
4/9/2018Morgan StanleyLower TargetOverweight ➝ Overweight$142.00 ➝ $76.00High
4/9/2018GabelliDowngradeBuy ➝ HoldMedium
4/9/2018Nomura SecuritiesLower TargetBuy$102.00Low
4/9/2018OppenheimerSet TargetHold$110.00 ➝ $65.00Low
4/6/2018Credit Suisse GroupSet TargetOutperform ➝ Outperform$145.00 ➝ $78.00Medium
4/6/2018SunTrust BanksReiterated RatingBuy$80.00Low
4/6/2018Raymond JamesSet TargetBuy$85.00High
4/6/2018GuggenheimReiterated RatingBuy ➝ NeutralHigh
4/6/2018William BlairReiterated RatingOutperform ➝ Market PerformHigh
4/5/2018BarclaysLower TargetOverweight ➝ Overweight$165.00 ➝ $135.00Low
2/28/2018Raymond JamesSet TargetBuy$159.00Medium
2/20/2018OppenheimerSet TargetHold$110.00Low
2/15/2018Raymond JamesReiterated RatingBuyLow
2/14/2018Credit Suisse GroupSet TargetBuy$145.00High
2/1/2018Nomura SecuritiesReiterated RatingBuyHigh
1/22/2018OppenheimerReiterated RatingHold$120.00 ➝ $110.00Low
1/3/2018BMO Capital MarketsReiterated RatingBuy$172.00Low
1/2/2018CitigroupReiterated RatingMarket Perform$135.00 ➝ $120.00High
1/2/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$136.00High
1/2/2018OppenheimerSet TargetHold$120.00High
12/12/2017Deutsche Bank AktiengesellschaftInitiated CoverageHold$106.00Medium
12/12/2017Raymond JamesReiterated RatingBuyMedium
12/5/2017CowenReiterated RatingBuyLow
11/21/2017Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$136.00 ➝ $120.00N/A
10/31/2017OppenheimerSet TargetHold$135.00N/A
10/31/2017BMO Capital MarketsBoost TargetOutperform$162.00 ➝ $166.00N/A
10/31/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
10/26/2017BMO Capital MarketsLower TargetOutperform$163.00 ➝ $162.00N/A
10/25/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
10/6/2017The Goldman Sachs GroupInitiated CoverageBuy$160.00N/A
10/6/2017Jefferies Financial GroupReiterated RatingBuyN/A
(Data available from 9/27/2017 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 36 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
  • 5 very positive mentions
  • 22 positive mentions
  • 5 negative mentions
  • 4 very negative mentions
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 10 very positive mentions
  • 38 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
  • 11 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 46 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 10 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 2 very positive mentions
  • 10 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Incyte logo
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Read More

Today's Range

Now: $66.44
Low: $65.88
High: $67.53

50 Day Range

MA: $72.78
Low: $66.18
High: $82.86

52 Week Range

Now: $66.44
Low: $61.91
High: $84.86


1,799,244 shs

Average Volume

1,526,619 shs

Market Capitalization

$14.78 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Incyte?

The following equities research analysts have issued research reports on Incyte in the last twelve months: BMO Capital Markets, Cantor Fitzgerald, Evercore ISI, Guggenheim, JMP Securities, Morgan Stanley, Oppenheimer Holdings Inc., Royal Bank of Canada, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, TheStreet, Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for INCY.

What is the current price target for Incyte?

12 Wall Street analysts have set twelve-month price targets for Incyte in the last year. Their average twelve-month price target is $84.92, suggesting a possible upside of 27.8%. JMP Securities has the highest price target set, predicting INCY will reach $108.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $63.00 for Incyte in the next year.
View the latest price targets for INCY.

What is the current consensus analyst rating for Incyte?

Incyte currently has 1 sell rating, 6 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in INCY, but not buy more shares or sell existing shares.
View the latest ratings for INCY.

What other companies compete with Incyte?

How do I contact Incyte's investor relations team?

Incyte's physical mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company's listed phone number is (302) 498-6700 and its investor relations email address is [email protected] The official website for Incyte is www.incyte.com. Learn More about contacing Incyte investor relations.